IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

Phase 3darovasertibcrizotinibPositive

AI Analysis

Summary

IDEAYA Biosciences and Servier announced the first patient dosed in OptimUM-11, a global Phase 3 registrational trial evaluating darovasertib and crizotinib combination as adjuvant therapy for uveal melanoma patients at high risk of metastasis.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in OptimUM-11 global Phase 3 registrational trial

Importance:6/10

Sentiment:

0.60

Phase 3 trialuveal melanomaregistrationalcombination therapyadjuvant therapy

Related Companies

$IDYA

Read the original article

Published by PR Newswire Biotech on September 9, 2026 10:00 AM

Read Original